scholarly journals Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

2019 ◽  
Vol 17 (6) ◽  
pp. 721-749 ◽  
Author(s):  
Martin S. Tallman ◽  
Eunice S. Wang ◽  
Jessica K. Altman ◽  
Frederick R. Appelbaum ◽  
Vijaya Raj Bhatt ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Myeloid Leukemia ◽  
Treatment Options ◽  
The United States ◽  
Nccn Guidelines ◽  
Younger Age ◽  
Acute Myeloid

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.

Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology

2003 ◽  
Vol 1 (4) ◽  
pp. 520 ◽  
Keyword(s):  
Clinical Trials ◽  
Acute Myeloid Leukemia ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Myeloid Leukemia ◽  
Treatment Options ◽  
Innovative Strategies ◽  
Recent Version ◽  
Acute Myeloid

The incidence of leukemia, along with its precursor, myelodysplasia, appears to be rising, particularly in the population over age 60. Recently an expanded panel of clinicians from the NCCN member institutions joined to update guidelines for the treatment of acute myeloid leukemia. Although there are some areas in which clinical trials have led to significant improvements in treatment, for the most part, recent trials have only served to highlight the continued need for innovative strategies to overcome this disease. These guidelines focus on outlining reasonable treatment options based on the information available. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

2017 ◽  
Vol 15 (7) ◽  
pp. 926-957 ◽  
Author(s):  
Margaret R. O'Donnell ◽  
Martin S. Tallman ◽  
Camille N. Abboud ◽  
Jessica K. Altman ◽  
Frederick R. Appelbaum ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Myeloid Leukemia ◽  
Acute Myeloid

International Adaptation and Use of NCCN Guidelines

2014 ◽  
Vol 12 (5S) ◽  
pp. 838-841 ◽  
Author(s):  
Ali Bazarbachi ◽  
Andrew D. Zelenetz
Keyword(s):  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
B Cell Lymphoma ◽  
The United States ◽  
Annual Conference ◽  
Nccn Guidelines ◽  
Adult T Cell Leukemia ◽  
Large B Cell Lymphoma ◽  
Modification Process

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) describe a continuum of cancer care in the United States, from initial diagnosis through treatment and referral to hospice beyond treatment. However, in many other countries, there are no regional or national clinical practice guidelines. In 2008, the NCCN-MENA (Middle East and North Africa) project was launched to adapt the NCCN Guidelines to this part of the world. During their joint presentation at the NCCN 19th Annual Conference, Dr. Ali Bazarbachi and Dr. Andrew D. Zelenetz explored the modification process of NCCN Guidelines for MENA and shared examples of how it improved the care of patients with adult T-cell leukemia or lymphoma and younger patients with diffuse large B-cell lymphoma—regardless of where they live.

Breast Cancer Clinical Practice Guidelines in Oncology

2003 ◽  
Vol 1 (2) ◽  
pp. 148 ◽  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Invasive Breast Cancer ◽  
The United States ◽  
Cancer Society ◽  
Nccn Guidelines ◽  
Recent Version

The American Cancer Society estimates that approximately 205,000 new cases of breast cancer were diagnosed in the United States in the year 2002, and approximately 40,000 patients will die of this disease. The NCCN guidelines discuss the complex and varied therapeutic options for patients with noninvasive or invasive breast cancer. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014–2017

2021 ◽  
pp. 1-9
Author(s):  
Mohammed W. Rahman ◽  
Niti U. Trivedi ◽  
Peter B. Bach ◽  
Aaron P. Mitchell
Keyword(s):  
Clinical Practice ◽  
Pharmaceutical Industry ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Clinical Decision Making ◽  
Guideline Development ◽  
Temporal Trends ◽  
The United States ◽  
Nccn Guidelines ◽  
Medical Oncologists

Background: Personal payments from the pharmaceutical industry to US physicians are common and are associated with changes in physicians’ clinical practice and interpretation of clinical trial results. We assessed temporal trends in industry payments to oncologists, with particular emphasis on payments to authors of oncology clinical practice guideline and on payments related to immunotherapy drugs. Methods: We included US physicians with active National Plan and Provider Enumeration System records and demographic data available in the Centers for Medicare & Medicaid Services Physician Compare system who had a specialty type of medical oncology or general internal medicine. Medical oncologists serving on NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Panels were identified manually. Industry payments, and the subset associated with PD-1/PD-L1 drugs, were identified in Open Payments, the federal repository of all transactions of financial value from industry to physicians and teaching hospitals, from 2014 to 2017. Results: There were 13,087 medical oncologists and 85,640 internists who received payments. The mean, annual, per-physician value of payments to oncologists increased from $3,811 in 2014 to $5,854 in 2017, and from $444 to $450 for internists; the median payment increased from $152 to $199 for oncologists and remained at $0 for internists. Oncologists who served on NCCN Guidelines Panels received a greater value in payments and experienced a greater relative increase: mean payments increased from $10,820 in 2014 to $18,977 in 2017, and median payments increased from $500 to $1,366. Among companies marketing PD-1/PD-L1 drugs, mean annual per-oncologist payments associated with PD-1/PD-L1 drugs increased from $28 to $773. Total per-oncologist payments from companies marketing PD-1/PD-L1 drugs experienced a 165% increase from 2014 to 2017, compared with a 31% increase among similar companies not marketing PD-1/PD-L1 drugs. Conclusions: Pharmaceutical industry payments increased for US oncologists from 2014 to 2017 more than for general internists. The increase was greater among oncologists contributing to clinical practice guidelines and among pharmaceutical companies marketing PD-1/PD-L1 drugs. The increasing flow of money from industry to US oncologists supports ongoing concern regarding commercial interests in guideline development and clinical decision-making.

Hepatobiliary Cancer Clinical Practice Guidelines in Oncology

2003 ◽  
Vol 1 (1) ◽  
pp. 94 ◽  
Keyword(s):  
United States ◽  
Clinical Practice ◽  
Gallbladder Cancer ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
The United States ◽  
Newly Diagnosed ◽  
Nccn Guidelines ◽  
Hepatobiliary Cancer ◽  
Recent Version

Hepatobiliary cancers are both common and highly lethal worldwide. However, in the United States, the incidence of hepatobiliary cancer is relatively low, with approximately 23,700 patients newly diagnosed each year. Gallbladder cancer is the most common of the hepatobiliary malignancies, accounting for approximately 30% of newly diagnosed cases in the United States. Along with summaries of the NCCN guidelines for the 4 subtypes of hepatobiliary cancer, this article includes a brief discussion of the epidemiology, pathology, etiology, staging, diagnosis, and treatment of each subtype. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals Acute Myeloid Leukemia: Advanced Practice Management From Presentation to Cure

2020 ◽  
Vol 11 (8) ◽  
Author(s):  
Meredith Beaton, RN, MSN, AG-ACNP ◽  
Glen J. Peterson, RN, DNP, ACNP ◽  
Kelly O'Brien, RN, MSN, ANP-C, ACNP-BC
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Performance Status ◽  
Treatment Options ◽  
Signs And Symptoms ◽  
The Elderly ◽  
Poor Performance Status ◽  
Curative Therapy ◽  
Initial Symptoms ◽  
Acute Myeloid

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, diagnosed in approximately 21,450 individuals annually in the US with nearly 11,000 deaths attributable to this disease (National Cancer Institute, 2020). Acute myeloid leukemia is a disease of the elderly, with the average age of diagnosis being 68 years old (Kouchkovsky & Abdul-Hay, 2016). It is a heterogeneous disease with widely varying presentations but universally carries a poor prognosis in the majority of those affected. Unfortunately, the 5-year overall survival rate remains poor, at less than 5% in patients over 65 years of age (Thein, Ershler, Jemal, Yates, & Baer, 2013). The landscape of AML is beginning to change, however, as new and improved treatments are emerging. Advanced practitioners (APs) are often involved in the care of these complex patients from the time of initial symptoms through diagnosis, treatment, and potentially curative therapy. It is vitally important for APs to understand and be aware of the various presentations, initial management strategies, diagnostic workup, and treatment options for patients with AML, especially in the elderly population, which until recently had few treatment options. This Grand Rounds article highlights the common presenting signs and symptoms of patients with AML in the hospital, including a discussion of the upfront clinical stability issues, oncologic emergencies, diagnostic evaluation, and current treatment options for elderly patients and those with poor performance status.

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

2021 ◽  
Vol 19 (3) ◽  
pp. 329-359
Author(s):  
Al B. Benson ◽  
Alan P. Venook ◽  
Mahmoud M. Al-Hawary ◽  
Mustafa A. Arain ◽  
Yi-Jen Chen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Systemic Therapy ◽  
Checkpoint Inhibitors ◽  
Therapy Options ◽  
Nccn Guidelines ◽  
Positive Treatment ◽  
Biomarker Testing

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These updates include recommendations for first-line use of checkpoint inhibitors for mCRC, that is deficient mismatch repair/microsatellite instability-high, recommendations related to the use of biosimilars, and expanded recommendations for biomarker testing. The systemic therapy recommendations now include targeted therapy options for patients with mCRC that is HER2-amplified, or BRAF V600E mutation–positive. Treatment and management of nonmetastatic or resectable/ablatable metastatic disease are discussed in the complete version of the NCCN Guidelines for Colon Cancer available at NCCN.org. Additional topics covered in the complete version include risk assessment, staging, pathology, posttreatment surveillance, and survivorship.

Sign in / Sign up

Export Citation Format

Share Document